Cough Science News
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
This month’s roundup explores placebo effects in RCC trials, the role of interoception in chronic cough, and the cost burden of persistent symptoms, plus insights from Dr. Nadia Giannetti.
New key cough science publications, Actigraph x Hyfe partnership and more
This year marked significant progress in cough monitoring, solidifying cough as a valuable biomarker in diverse therapeutic areas
New findings on refractory chronic cough (RCC), pulmonary tuberculosis, and pulmonary fibrosis. Plus latest white papers by Hyfe.
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News, August 2024 - Explore studies on cough variability, acute cough duration, and the cost burden of chronic cough. Plus, discover the world’s most comprehensive collection of cinematic coughs and upcoming events in cough science
CougH Science News July 2024 - latest in cough science. Insights on cough detection algorithms, pulmonary fibrosis, asthma diagnosis from cough sounds, and more. Plus, watch expert discussions and stay updated on upcoming events
Hyfe Cough Science News, June 2024. Latest research on cough in fibrotic ILD, high-dose inhaled corticosteroids for chronic cough, and family physicians’ approaches to managing chronic cough. Plus, insights from leading researchers and upcoming events
Cough Science News May 2024 - studies on cough monitoring for COVID-19 surveillance, the effectiveness of codeine for chronic cough, factors in refractory cough in IPF, and more. Plus, insights from researchers and upcoming events
Hyfe Cough Science News, March 2024 - insights on chronic cough management in the UK, common triggers in cough hypersensitivity, and a review of treatments for refractory cough. Plus, expert Q&A and upcoming cough science events.
Here’s What’s Inside
Key Takeaway: This study evaluated patients with chronic refractory cough (CRC), with and without co-occurring oropharyngeal dysphagia (DYS), who underwent cough suppression therapy. After treatment, patients with both CRC and DYS showed significant improvement in self-reported swallowing severity, reaching levels comparable to those without DYS. Both groups also experienced similar reductions in cough severity.
Why It Matters: Many patients with CRC also experience swallowing difficulties, yet these symptoms are often addressed separately. This study suggests that cough suppression therapy may have dual benefits—improving both cough control and swallowing function—when there is no aspiration risk. It supports the use of cough suppression therapy as a more integrated approach to upper airway management.
Key Takeaway: This expert review explores the potential of dual-action drugs that activate kappa opioid receptors (KOR) while blocking mu opioid receptors (MOR) to treat chronic cough. A standout candidate is nalbuphine ER, which showed a 76% reduction in 24-hour cough frequency in a recent Phase 2 trial in patients with IPF-related cough, without the concerns linked to traditional opioids.
Why It Matters: Refractory chronic cough often resists standard treatment, and existing opioid-based therapies carry risks of sedation and dependency. This paper outlines how targeting opioid receptor pathways, both centrally and peripherally, could offer a new class of effective and safer antitussives, expanding options for patients with persistent cough.
Key Takeaway: This systematic review identified only 14 studies over the past decade that assessed quality of life in children with chronic cough. Just one tool, the Child Cough-specific Quality of Life questionnaire (CC-QoL), was developed and validated specifically for this group. No studies reported culturally adapted tools, and most relied solely on parent reports, despite evidence that child and parent perceptions often differ.
Why It Matters: Chronic cough can significantly affect children’s wellbeing, but the lack of validated, child-focused and culturally sensitive assessment tools limits our ability to measure its true impact. More development in this area is urgently needed to support both research and care.
In this exclusive conversation, Hyfe’s Reid Moorsmith breaks down the science, strategy, and future of the first digital therapeutic for chronic cough. From behavioral therapy and real-time monitoring to clinical workflows and pharma partnerships, this is a must-watch for anyone working in digital health, respiratory care, or therapeutic innovation.
